Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) is a Healthcare company (Biotechnology) with a market capitalization of $1.2B. The Maz Rating grades it against the other companies in its sector.
Avalyn Pharma Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $27.92, Avalyn Pharma Inc. Common Stock trades at 3.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -62.8%, return on invested capital of -29.5% and a free cash flow yield of -8.4%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 25.76. Over the past 52 weeks the share price ranged from $22.24 to $40.17, with a beta of -1.13.
Avalyn Pharma Inc. Common Stock does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.